Unlike colon and prostate cancer treatment, in which combined SV.IL-12 and OX40 antibody clearly was most efficacious, MOSEC.Fluc.p11 tumors were eradicated almost as well with either SV.IL-12 or SV.IgGOX40.IL-12 vectors. This evidence concerns the gene TNFRSF4 and prostate carcinoma.